Abstract
Executive Summary
This report includes defined and up to date development strategies for 283
lung cancer therapeutic drugs (>317 projects) within the portfolio of 167
investigators, from Ceased to Marketed. In total the report assesses three
different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small
Cell Lung Cancer and Lung Cancer (general). The report is written for you to
understand and assess the impact of competitor entry and corresponding changes
to development strategies for your own portfolio products. It serves as an
external commercial advocate for pharmaceutical companies' portfolio planning
and new product planning by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting lung cancer
sub-indications that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report will also be an important part of creating and implementing a
market development plan for any lung cancer therapeutic drugs to ensure that
the optimal market conditions exist by the time the product is commercialized.
| 
View Cart
